Cambridge Healthtech Institute’s 4th Annual

Immuno-Oncology Advances

Translational Strategies, Small Molecule Targets and Immune Profiling

June 2-4, 2020


Immuno-oncology research and the subsequent development of immunotherapies continue to rapidly advance the fight against cancer. First-generation agents that achieved remarkable clinical success have inspired researchers to pursue a variety of new treatment modalities and created a robust development landscape centered on combinations strategies. The 4th Annual Immuno-Oncology Advances conference, part of World Pharma Week, will feature three key areas that include preclinical and translational strategies, small molecule targets in immuno-oncology, and immune profiling and monitoring.

Coverage will include, but is not limited to:

TRANSLATIONAL ONCOLOGY AND IMMUNO-ONCOLOGY

Leveraging Multi-Targeting for More Effective Cancer Immunotherapy
Dmitri Wiederschain, PhD, Global Head, Immuno-Oncology Research Therapeutic Area, Sanofi

External R&N in Immuno-Oncology
Michael Woo, PhD, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

NOVEL THERAPEUTICS AND TECHNOLOGIES

CD3 Bispecific Platform
Divya Mathur, PhD, Associate Research Fellow, Targeted Immunotherapy, Pfizer-Oncology

Bispecific T Cell Engagers: Overview of Amgen‘s BiTE® Pipeline
Benno Rattel, PhD, Executive Director Research Amgen, CBSS, Amgen

Immunoregulatory Roles Exerted by Specific Subsets of Mesenchymal Cells in The Tumor Microenvironment
Viviana Cremasco, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis

Preclinical and Translational Imaging Methods in the Development of Immuno-Oncology Therapeutics
Charles Glaus, PhD, Scientific Director, Quantitative & Translational Science, Imaging, Takeda Pharmaceuticals

Friends & Enemies: Spatial Mapping of Regulatory T Lymphocytes in Inflammatory Microenvironments
Shawn O’Neill, DVM, PhD, Senior Director, Global Pathology & Investigative Toxicology, Global Microscopic Imaging Lead, Drug Safety Research & Development, Pfizer Worldwide Research & Development

PROFILING THE TUMOR MICROENVIRONMENT

The Tumor Immune Microenvironment of Pre-Malignant Lesion in the Pancreas
Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology and Oncology, The Johns Hopkins Hospital

Multiplex Immunofluorescence Tyramide Signal Amplification and Multispectral Imaging Assay to Support Translational Oncology Studies
Edwin Roger Parra Cuentas, MD, PhD, Assistant Professor, Translational Molecular Pathology, Director of the Multiplex Immunofluorescence and Image Analysis Laboratory, MD Anderson Cancer Center

Talk Title to be Announced
Dirk Brockstedt, PhD, CSO, RAPT Therapeutics